madman
Super Moderator
* Treatment should be embedded in structured monitoring of hematocrit, blood pressure, renal and hepatic function, and cardiac rhythm, and coupled with active management of coexisting obesity, sleep apnea, diabetes, hypertension, and dyslipidemia, each of which independently influences AF risk
Figure 1 Schematic synthesis of the U-shaped relationship between serum testosterone and risk of incident AF, synthesized from the restricted cubic spline analyses of Xu et al (UK Biobank) (5) and Tran et al (ASPREE) (6). The curve is conceptual and does not represent a pooled quantitative estimate; the risk nadir lies within the mid-physiologic range (shaded therapeutic window). In Tran et al, the elevated-risk association at high testosterone was statistically significant, whereas the low-testosterone association did not reach significance. Axis conversion: 1 nmol/L = 28.82 ng/dL.
Conclusion
In clinical practice, restoring testosterone toward the physiologic mid-range (approximately 350-550 ng/dL) is a reasonable therapeutic goal for symptomatic hypogonadal men, but this target is an aspiration rather than an absolute: it must be individualized using calculated free testosterone when SHBG is abnormal and, above all, subordinated to the maintenance of a normal hematocrit, which remains the principal dose-limiting safety constraint of TRT (28, 29). Treatment should be embedded in structured monitoring of hematocrit, blood pressure, renal and hepatic function, and cardiac rhythm, and coupled with active management of coexisting obesity, sleep apnea, diabetes, hypertension, and dyslipidemia, each of which independently influences AF risk. Because testosterone reference ranges are age-dependent and total testosterone is an imperfect marker of androgen action, decision-making in older and comorbidmen should incorporate free testosterone, SHBG, and hepatic and renal function. Stable-pharmacokinetic formulations are generally preferred in men with elevated cardiovascular or arrhythmic risk. Prospective dose-response trials stratified by baseline cardiovascular substrate and incorporating systematic ECG and free-testosterone assessment are needed to define an optimal therapeutic window and to operationalize the U-shape into clinical guidance with confidence.
Figure 1 Schematic synthesis of the U-shaped relationship between serum testosterone and risk of incident AF, synthesized from the restricted cubic spline analyses of Xu et al (UK Biobank) (5) and Tran et al (ASPREE) (6). The curve is conceptual and does not represent a pooled quantitative estimate; the risk nadir lies within the mid-physiologic range (shaded therapeutic window). In Tran et al, the elevated-risk association at high testosterone was statistically significant, whereas the low-testosterone association did not reach significance. Axis conversion: 1 nmol/L = 28.82 ng/dL.
Conclusion
In clinical practice, restoring testosterone toward the physiologic mid-range (approximately 350-550 ng/dL) is a reasonable therapeutic goal for symptomatic hypogonadal men, but this target is an aspiration rather than an absolute: it must be individualized using calculated free testosterone when SHBG is abnormal and, above all, subordinated to the maintenance of a normal hematocrit, which remains the principal dose-limiting safety constraint of TRT (28, 29). Treatment should be embedded in structured monitoring of hematocrit, blood pressure, renal and hepatic function, and cardiac rhythm, and coupled with active management of coexisting obesity, sleep apnea, diabetes, hypertension, and dyslipidemia, each of which independently influences AF risk. Because testosterone reference ranges are age-dependent and total testosterone is an imperfect marker of androgen action, decision-making in older and comorbidmen should incorporate free testosterone, SHBG, and hepatic and renal function. Stable-pharmacokinetic formulations are generally preferred in men with elevated cardiovascular or arrhythmic risk. Prospective dose-response trials stratified by baseline cardiovascular substrate and incorporating systematic ECG and free-testosterone assessment are needed to define an optimal therapeutic window and to operationalize the U-shape into clinical guidance with confidence.
